4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-003405
CHIEF FINANCIAL OFFICER sold 1,000 shares at $22.52 ($22,524)
- CHIEF FINANCIAL OFFICER acquired 1,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hohl Benjamin · CHIEF FINANCIAL OFFICER
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-02-05 | Exercise or conversion : show line 1 in the form 10b5-1 | +1,000 | $2.48 | $2,480 | 14,000 | D |
| 2025-02-05 | Sale : show line 2 in the form 10b5-1 | −1,000 | $22.52 | $22,524 | 13,000 | D |
| Open-market sales · 1,000 sh · avg $22.52 · $22,524 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-02-05 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) | −1,000 | 146,056 | D |
Loading xslF345X05/form4-02082025_120242.xml…